MA29394B1 - Anticorps - Google Patents

Anticorps

Info

Publication number
MA29394B1
MA29394B1 MA30301A MA30301A MA29394B1 MA 29394 B1 MA29394 B1 MA 29394B1 MA 30301 A MA30301 A MA 30301A MA 30301 A MA30301 A MA 30301A MA 29394 B1 MA29394 B1 MA 29394B1
Authority
MA
Morocco
Prior art keywords
antibodies
antibody
candidose
dabs
virulence
Prior art date
Application number
MA30301A
Other languages
English (en)
Inventor
Steven Grant
Haiqun Liu
Antonio Cassone
Bernardis Flavia De
Original Assignee
Domantis Ltd
Antonio Cassone
Bernardis Flavia De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505489A external-priority patent/GB0505489D0/en
Priority claimed from GBGB0519883.3A external-priority patent/GB0519883D0/en
Application filed by Domantis Ltd, Antonio Cassone, Bernardis Flavia De filed Critical Domantis Ltd
Publication of MA29394B1 publication Critical patent/MA29394B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE LE DOMAINE DES ANTICORPS ET, EN PARTICULIER, LE DOMAINE DES ANTICORPS (DABS) QUI RECONNAISSENT LES TRAITS DE VIRULENCE DE CANDIDA SPP. ET QUI CONFÈRENT UNE PROTECTION PASSIVE CONTRE LA CANDIDOSE.
MA30301A 2005-03-18 2007-10-12 Anticorps MA29394B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0505489A GB0505489D0 (en) 2005-03-18 2005-03-18 Antibodies
GBGB0519883.3A GB0519883D0 (en) 2005-09-29 2005-09-29 Antibodies

Publications (1)

Publication Number Publication Date
MA29394B1 true MA29394B1 (fr) 2008-04-01

Family

ID=36808786

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30301A MA29394B1 (fr) 2005-03-18 2007-10-12 Anticorps

Country Status (12)

Country Link
US (1) US8092800B2 (fr)
EP (1) EP1863845A2 (fr)
JP (1) JP2008533115A (fr)
KR (1) KR20080003351A (fr)
AU (1) AU2006224438A1 (fr)
CA (1) CA2601115A1 (fr)
EA (1) EA200701766A1 (fr)
IL (1) IL185781A0 (fr)
MA (1) MA29394B1 (fr)
MX (1) MX2007011356A (fr)
NO (1) NO20074616L (fr)
WO (1) WO2006097689A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097689A2 (fr) 2005-03-18 2006-09-21 Domantis Limited Anticorps
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20090081196A1 (en) * 2007-02-16 2009-03-26 Istituto Superiore Di Sanita Medicaments for fungal infections
AR073905A1 (es) * 2008-10-21 2010-12-09 Domantis Ltd Ligandos que tienen especificidad de union por dc-sign
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
CA2871081A1 (fr) * 2011-04-21 2012-10-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccins de peptide et conjugue pour infections fongiques
CN107663239A (zh) * 2016-12-28 2018-02-06 天津天锐生物科技有限公司 一种识别hla‑a2/nlvpmvatv的单域抗体
CN112552402B (zh) * 2018-09-27 2022-08-12 暨南大学 一种抗人egfr的纳米抗体与应用
WO2020130838A2 (fr) * 2018-12-21 2020-06-25 Qvq Holding B.V. Anticorps pour la prévention ou le traitement de la candidose
CN112646035B (zh) * 2020-12-25 2022-06-24 暨南大学 Egfr的亲和力成熟结合蛋白及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046245A2 (fr) 1999-02-01 2000-08-10 Schering Aktiengesellschaft Proteines antibiotiques humaines
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
EP2135879A3 (fr) * 2002-06-28 2010-06-23 Domantis Limited Ligand
JP2006520584A (ja) * 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
CN101412759A (zh) * 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
EP1603948A1 (fr) * 2003-03-14 2005-12-14 Pharmacia Corporation Anticorps specifiques du recepteur d'igf-i pour le traitement de cancers
DK1639011T3 (da) * 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
DE05733048T1 (de) 2004-04-06 2007-05-10 Affibody Ab Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006097689A2 (fr) 2005-03-18 2006-09-21 Domantis Limited Anticorps
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections

Also Published As

Publication number Publication date
WO2006097689A2 (fr) 2006-09-21
AU2006224438A1 (en) 2006-09-21
WO2006097689A3 (fr) 2007-03-15
KR20080003351A (ko) 2008-01-07
NO20074616L (no) 2007-11-27
MX2007011356A (es) 2008-03-10
US8092800B2 (en) 2012-01-10
IL185781A0 (en) 2008-01-06
JP2008533115A (ja) 2008-08-21
CA2601115A1 (fr) 2006-09-21
US20080193450A1 (en) 2008-08-14
EP1863845A2 (fr) 2007-12-12
EA200701766A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
MA29394B1 (fr) Anticorps
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
TW200732349A (en) Anti-OX40L antibodies and methods using same
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
WO2008034120A3 (fr) Segments de liaison polymères à base de lysine
ATE518010T1 (de) Aktive oberflächengekoppelte polymerasen
WO2007120656A3 (fr) Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
EP1839250A4 (fr) Generation et/ou mise a disposition d'offres promotionnelles dynamiques telles que des coupons et des publicites
MY139142A (en) Short corridor progressive addition lenses with reduced unwanted astigmatism
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
SG155163A1 (en) Pharmacokinetically improved compounds
DK1414956T3 (da) Höjt påvirkningsresistente granula
WO2006108075A3 (fr) Compositions et methodes accroissant la sensibilite aux medicaments et traitant les infections et maladies presentant une resistance aux medicaments
HK1103391A1 (en) Cationic lipids and methods of use
MA29528B1 (fr) Agents de fixation
TW200501277A (en) Nanofiber surfaces for use in enhanced surface area applications
TW200628534A (en) Retention and drainage aids
MY144318A (en) Methods of treating hiv infection.
WO2007019373A3 (fr) Nouvelles formulations contenant du fenofibrate et de la statine et procedes de traitement associes
WO2005074925A8 (fr) Compositions contenant de la piperacilline et du tazobactame